PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
January 10, 2018Clinical Pharmacology & Therapeutics386 citationsOpen Access

Physiologically Based Pharmacokinetic Model Qualification and Reporting Procedures for Regulatory Submissions: A Consortium Perspective

View Full Paper
MSMohamad ShebleyPSPunam SandhuARArian Emami Riedmaier

Key Points

  • To discuss the qualification and verification of physiologically based pharmacokinetic models for regulatory submissions.
  • Provided an overview of the Simcyp Consortium's collective experiences with PBPK platforms.
  • Reviewed recent guidelines from the EMA and FDA on PBPK analyses and reporting.
  • Highlighted the importance of regulatory submissions for PBPK analyses across different applications.
  • Recommended increased clarity and flexibility in guidelines to enhance PBPK analyses acceptance.

Abstract

This work provides a perspective on the qualification and verification of physiologically based pharmacokinetic (PBPK) platforms/models intended for regulatory submission based on the collective experience of the Simcyp Consortium members. Examples of regulatory submission of PBPK analyses across various intended applications are presented and discussed. European Medicines Agency (EMA) and US Food and Drug Administration (FDA) recent draft guidelines regarding PBPK analyses and reporting are encouraging, and to advance the use and acceptability of PBPK analyses, more clarity and flexibility are warranted.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Shebley et al. (2018) studied this question.

synapsesocial.com/papers/69f3e67fe148b701999f6636https://doi.org/10.1002/cpt.1013
Ask AI
Helpful
Bookmark
Share
View Full Paper